Abstract
South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antitubercular Agents / therapeutic use*
-
Coinfection
-
Diarylquinolines / administration & dosage
-
Diarylquinolines / therapeutic use*
-
Drug Substitution*
-
Drug Therapy, Combination
-
Female
-
HIV Infections
-
Humans
-
Male
-
Middle Aged
-
Mycobacterium tuberculosis / drug effects*
-
Retreatment
-
Retrospective Studies
-
Rifampin / therapeutic use
-
South Africa
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / diagnosis
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / microbiology*
Substances
-
Antitubercular Agents
-
Diarylquinolines
-
bedaquiline
-
Rifampin